Tykerb (lapatinib ditosylate tablets – Novartis, generic) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has unresectable, advanced, or metastatic disease
• Patient has human epidermal receptor 2 (HER2)-amplified disease
• Patient has wild-type RAS and BRAF disease
• Patient meets ONE of the following: (i) Patient has tried at least one chemotherapy regimen OR (ii) Patient is not a candidate for intensive therapy according to the prescriber
• The medication is used in combination with trastuzumab
• Patient has not been previously treated with a HER2-inhibitor

Approval duration

1 year